Leerink Partnrs Has Bullish Forecast for uniQure Q3 Earnings

uniQure N.V. (NASDAQ:QURE) – Investment analysts at Leerink Partnrs upped their Q3 2025 earnings per share (EPS) estimates for shares of uniQure in a report issued on Tuesday, July 29th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings of ($0.93) per share for the quarter, up from their prior estimate of ($1.11). The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. Leerink Partnrs also issued estimates for uniQure’s FY2025 earnings at ($1.71) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($1.06) EPS and FY2029 earnings at $1.10 EPS.

A number of other equities research analysts also recently weighed in on the company. Guggenheim reiterated a “buy” rating and issued a $28.00 price target on shares of uniQure in a report on Monday, May 12th. Chardan Capital lowered their price objective on uniQure from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. Cantor Fitzgerald set a $47.00 price objective on uniQure in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of uniQure in a research note on Thursday, May 29th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $36.55.

uniQure Price Performance

Shares of NASDAQ QURE opened at $13.69 on Friday. uniQure has a twelve month low of $4.45 and a twelve month high of $19.18. The company has a current ratio of 9.98, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53. The company has a market capitalization of $751.17 million, a price-to-earnings ratio of -3.49 and a beta of 0.11. The business has a 50 day simple moving average of $14.83 and a 200-day simple moving average of $13.69.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. The business had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million.

Insider Activity at uniQure

In other uniQure news, Director Robert Gut sold 3,336 shares of the business’s stock in a transaction on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $48,205.20. Following the completion of the transaction, the director owned 56,879 shares in the company, valued at approximately $821,901.55. The trade was a 5.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jeannette Potts sold 4,670 shares of the business’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $15.14, for a total value of $70,703.80. Following the transaction, the insider owned 115,073 shares of the company’s stock, valued at $1,742,205.22. This trade represents a 3.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,144 shares of company stock worth $322,426 in the last ninety days. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in QURE. Avoro Capital Advisors LLC acquired a new position in uniQure during the 4th quarter worth $38,410,000. Vestal Point Capital LP boosted its position in uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock worth $50,801,000 after acquiring an additional 1,767,572 shares during the period. RTW Investments LP lifted its holdings in shares of uniQure by 8,936.3% in the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock valued at $15,958,000 after buying an additional 893,625 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of uniQure by 81.3% in the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after buying an additional 794,459 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in shares of uniQure in the fourth quarter valued at $13,245,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.